Yeleswaram Krishnaswamy 4

What Happened
Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), sold 20,225 shares on April 17, 2026. The reported weighted-average sale price was $39.99 per share, for total proceeds of approximately $808,844. This was a sale (code S) — sales are often routine dispositions rather than a direct bullish signal.

Key Details

• Transaction date: 2026-04-17 (reported on Form 4 filed 2026-04-21).
• Price: weighted average $39.99; individual trade prices ranged from $39.90 to $40.38 (footnote).
• Total shares sold: 20,225; total proceeds ≈ $808,844.
• Post-transaction holdings: Not disclosed in the supplied excerpt of the filing.
• Footnotes:
  • F1 — Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted December 10, 2025 (prearranged plan).
  • F2 — The price is a weighted average; the filer will provide a per-price breakdown on request.
• Timeliness: Filed 2026-04-21 for a 2026-04-17 trade. Form 4s are typically due within two business days of a transaction, so this filing appears outside that usual window.

Context
Because the sale was executed under a Rule 10b5-1 plan, it was prearranged and may reflect planned liquidity rather than contemporaneous insider views on the company. For retail investors, purchases generally carry more informational weight than routine sales; this filing documents proceeded disposition of holdings totaling about $0.8M.